--- title: "Heron Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 37.67 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295403602.md" datetime: "2026-08-10T12:02:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295403602.md) - [en](https://longbridge.com/en/news/295403602.md) - [zh-HK](https://longbridge.com/zh-HK/news/295403602.md) --- # Heron Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 37.67 M Revenue: As of FY2026 Q2, the actual value is USD 37.67 M, missing the estimate of USD 42.2 M. EPS: As of FY2026 Q2, the actual value is USD -0.03. EBIT: As of FY2026 Q2, the actual value is USD -2.044 M. ### Financial Highlights (Three Months Ended June 30, 2026) #### Total Net Revenue Heron Therapeutics, Inc. reported total net revenue of $37.7 million for Q2 2026, marking a 9% increase from Q1 2026. Total net revenue for the three months ended June 30, 2026, was $37,666 thousand, an increase of 1.3% compared to $37,200 thousand in the same period of 2025. #### Segment Revenue - **Acute Care:** Net revenue for the Acute Care segment increased by 43.9% year-over-year to $15,333 thousand for the three months ended June 30, 2026, up from $10,653 thousand in 2025. - **APONVIE®:** Contributed $4,277 thousand in net revenue, a 73.6% increase from $2,464 thousand in 2025. - **ZYNRELEF®:** Generated $11,056 thousand in net revenue, a 35.0% increase from $8,189 thousand in 2025. - **Oncology:** Net revenue for the Oncology segment decreased by -15.9% year-over-year to $22,333 thousand for the three months ended June 30, 2026, down from $26,547 thousand in 2025. - **CINVANTI®:** Contributed $21,793 thousand in net revenue, a -9.7% decrease from $24,143 thousand in 2025. - **SUSTOL®:** Generated $540 thousand in net revenue, a -77.5% decrease from $2,404 thousand in 2025. #### Gross Profit Gross profit for the three months ended June 30, 2026, was $26,094 thousand, a decrease from $27,343 thousand in the prior year period. #### Operating Expenses Total operating expenses for the three months ended June 30, 2026, were $28,138 thousand, a decrease from $28,980 thousand in 2025. Research and development (R&D) expenses were $2,702 thousand in 2026, down from $2,934 thousand in 2025. General and administrative (G&A) expenses were $11,276 thousand in 2026, down from $14,471 thousand in 2025. Sales and marketing (S&M) expenses were $14,160 thousand in 2026, up from $11,575 thousand in 2025. #### Operating Profit/Loss Loss from operations for the three months ended June 30, 2026, was - $2,044 thousand, compared to a loss of - $1,637 thousand in 2025. #### Net Income/Loss Net loss for the three months ended June 30, 2026, was - $5,489 thousand, compared to a net loss of - $2,381 thousand in 2025. #### Adjusted EBITDA Adjusted EBITDA for the three months ended June 30, 2026, was $3,177 thousand, up from $2,218 thousand in 2025. ### Financial Highlights (Six Months Ended June 30, 2026) #### Total Net Revenue Total net revenue for the six months ended June 30, 2026, was $72,377 thousand, a decrease of -4.9% compared to $76,103 thousand in the same period of 2025. #### Segment Revenue - **Acute Care:** Net revenue for the Acute Care segment increased by 38.2% year-over-year to $28,961 thousand for the six months ended June 30, 2026, up from $20,954 thousand in 2025. - **APONVIE®:** Contributed $7,670 thousand in net revenue, a 62.4% increase from $4,724 thousand in 2025. - **ZYNRELEF®:** Generated $21,291 thousand in net revenue, a 31.2% increase from $16,230 thousand in 2025. - **Oncology:** Net revenue for the Oncology segment decreased by -21.3% year-over-year to $43,416 thousand for the six months ended June 30, 2026, down from $55,149 thousand in 2025. - **CINVANTI®:** Contributed $42,328 thousand in net revenue, a -15.2% decrease from $49,886 thousand in 2025. - **SUSTOL®:** Generated $1,088 thousand in net revenue, a -79.3% decrease from $5,263 thousand in 2025. #### Gross Profit Gross profit for the six months ended June 30, 2026, was $50,167 thousand, a decrease from $57,789 thousand in the prior year period. #### Operating Expenses Total operating expenses for the six months ended June 30, 2026, were $56,976 thousand, an increase from $56,272 thousand in 2025. Research and development (R&D) expenses were $5,087 thousand in 2026, down from $5,213 thousand in 2025. General and administrative (G&A) expenses were $23,421 thousand in 2026, down from $27,173 thousand in 2025. Sales and marketing (S&M) expenses were $28,468 thousand in 2026, up from $23,886 thousand in 2025. #### Operating Profit/Loss Loss from operations for the six months ended June 30, 2026, was - $6,809 thousand, compared to income of $1,517 thousand in 2025. #### Net Income/Loss Net loss for the six months ended June 30, 2026, was - $13,600 thousand, compared to a net income of $254 thousand in 2025. #### Adjusted EBITDA Adjusted EBITDA for the six months ended June 30, 2026, was $2,524 thousand, down from $8,434 thousand in 2025. #### Cash and Investments Heron Therapeutics, Inc. ended Q2 2026 with $42.7 million in cash, cash equivalents, and short-term investments. As of June 30, 2026, cash and cash equivalents were $20,721 thousand and short-term investments were $21,943 thousand. ### Outlook / Guidance Heron Therapeutics, Inc. withdrew its previously issued full-year 2026 financial guidance for net product sales and Adjusted EBITDA due to the inability to reliably forecast the timing or terms of potential generic entry for CINVANTI® following a June 2026 court decision. In response, the company paused sales force expansion, tightened spending, and is now considering strategic alternatives. ### Related Stocks - [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md) ## Related News & Research - [HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty](https://longbridge.com/en/news/295405345.md) - [Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook](https://longbridge.com/en/news/295404922.md) - [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md) - [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md) - [ESS Tech reschedules Q2 2026 results conference call to Tuesday evening](https://longbridge.com/en/news/295407778.md)